期刊
EUROPEAN JOURNAL OF PHARMACOLOGY
卷 704, 期 1-3, 页码 70-77出版社
ELSEVIER
DOI: 10.1016/j.ejphar.2013.02.015
关键词
Salvianolic acid B; Amyloid beta protein; Alzheimer's disease; Neuroprotection
资金
- Korea Food and Drug Administration [06082KFDA230, 09112KFDA989]
Salvianolic acid B (SalB) is a polyphenolic compound found in Salvia miltiorrhiza Bunge that has several anti-oxidative and anti-inflammatory effects. In the present study, we investigated whether SalB has neuroprotective effects in an amyloid beta (A beta) peptide-induced Alzheimer's disease mouse model. Mice were injected with A beta(25-35) peptide intracerebroventricularly and were subsequently administered SalB once daily for 7 days. Subchronic SalB administration (10 mg/kg) significantly ameliorated the A beta(25-35) peptide-induced memory impairment in the passive avoidance task (P < 0.05). SalB treatment also reduced the number of activated microglia and astrocytes that were observed during the inflammatory reaction after the administration of the A beta(25-35) peptide. Moreover, SalB markedly reduced inducible nitric oxide synthase and cyclooxygenase-2 expression levels and thiobarbituric acid reactive substances, which were increased by the administration of the A beta(25-35) peptide. Furthermore, SalB administration significantly rescued the A beta(25-35) peptide-induced decrease of choline acetyltransferase and brain-derived neurotrophic factor protein levels. These results suggest that SalB exerts neuroprotective activity via anti-inflammatory and anti-oxidative effects and that SalB may be a potential candidate for Alzheimer's disease therapy. (C) 2013 Elsevier By. All rights reserved.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据